The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
But chair Doug McKay says Hassall had the unanimous support of Vector board.
Institutional shareholders take-up 91% of rights issue and placement swallows the rest, raising gross proceeds of $593m.
The listed probiotic maker will come out of a trading halt this morning after telling the market it would take legal action.
Trigger for $700m capital raise was resolution of Iplex crisis, not disappointing bids for residential assets, says incoming CEO.
New York-based hedge fund Ampfield Management has reduced its holding in the transport tech company.
Cash will pay down debt and reduce pressure to sell assets, company said.
Exchange says work on rebrand planning began some years ago, but design and implementation only kicked off this year.
Analysts at Forsyth Barr drop recommendation to ‘neutral’ from ‘outperform’.
One analyst sees an 80% chance of ComCom approval for Contact’s Manawa buy, another sees 50%. Both see political point scoring as the main risk.